|
000
| 01475cam 2200349zi 4500 |
|---|
| 001 | 9.919196 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230420082429 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230116e202302 onc ob f000 0 eng d |
|---|
| 020 | |a9780660471129 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 045 | |ay2y2 |
|---|
| 086 | 1 |aHP40-331/2023E-PDF |
|---|
| 245 | 00|aNirmatrelvir/ritonavir implementation in Canada : |bsummary evaluation report : January to August 2022. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cFebruary 2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (iv, 36 pages) |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Mise en œuvre du nirmatrelvir/ritonavir au Canada : rapport d'évaluation sommaire : de janvier à août 2022. |
|---|
| 500 | |a"Pub.: 220700." |
|---|
| 504 | |aIncludes bibliographical references. |
|---|
| 650 | 0|aCOVID-19 (Disease)|xTreatment|zCanada|xEvaluation. |
|---|
| 650 | 0|aAntiviral agents|xTherapeutic use|zCanada|xEvaluation. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 775 | 08|tMise en œuvre du nirmatrelvir/ritonavir au Canada : |w(CaOODSP)9.919197 |
|---|
| 856 | 40|qPDF|s399 KB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-331-2023-eng.pdf |
|---|